Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Hsinchu, Taiwan , Jan. 09, 2020 (GLOBE NEWSWIRE) -- Andes Technology (TWSE: 6533), a leading supplier of high efficiency, low-power 32/64-bit RISC-V processor cores, has cooperated with more than 70...
-
Hsinchu Taiwan, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Andes Technology, a leading Asia-based supplier of high-performance low-power compact 32/64-bit RISC-V CPU cores and a founding Platinum member of...
-
San Jose, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Andes Technology, a leading supplier of high-performance low-power compact 32/64-bit RISC-V CPU cores and a founding member of the RISC-V Foundation,...
-
Hsinchu, Taiwan and San Jose, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Andes Technology Corporation, the world leader in RISC-V CPU solutions, announces AndesCore™ 45-series CPU cores today. It is...
-
Hsinchu, Taiwan and San Jose, California, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Andes Technology Corp. Ground-Breaking 27-Series Processor New Pipeline Andes announces AndesCore™ 27-series CPU...
-
Hsinchu Taiwan, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Andes Technology Corporation (TWSE: 6533), a founding member of the RISC-V Foundation and the leading supplier of 32/64-bit embedded CPU cores with...
-
Hsinchu, Taiwan, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Today, Secure-IC, the embedded security solutions provider from France specialized in embedded cybersecurity to protect against attacks, enters a...
-
サンディエゴ発 , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Crown Bioscience Inc.(以下「CrownBio」) は、創薬研究において臨床予測性が高い患者由来異種移植(patient-derived xenograft、以下「PDX」)モデルを新たに提供すべく、NEXT...
-
聖地牙哥, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Crown Bioscience 今天宣佈與 NEXT Oncology 開展策略性合作,為臨床前藥物開發提供新的臨床相關 PDX 模型。根據該協議,在未來五年,CrownBio 將擔任 NEXT Oncoloy 所有原發腫瘤 PDX 模型的獨家全球商業化合作夥伴。 ...
-
圣地亚哥, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Crown Bioscience今天宣布与NEXT Oncology的战略合作,以提供用于临床前药物开发的新型临床相关PDX模型。该合作协议确立了CrownBio将成为NEXT Oncology未来5年建立的所有原发肿瘤PDX模型的全球独家商业化合作伙伴关系。 ...